热门资讯> 正文
GSK预计2025年利润增长更高
2025-10-29 22:25
- GSK (GSK) is up ~7% in Wednesday trading after reporting Q3 results that beat on both lines and updating its earnings growth projection for 2025.
- The drugmaker now sees core earnings per share to increase 10%-12%, up from the top end of 6%-8% prior. Consensus is $4.34.
- While revenue growth in Q3 was ~5% year over year, GSK benefitted in the third quarter from particularly strong sales in the following segments: Specialty Medicines £3.4B (+16%); Respiratory, Immunology & Inflammation £1.0B (+15%); Oncology £0.5B (+39%); and HIV £1.9B (+12%).
- In its vaccines portfolio, Arexvy had the highest growth of 36% to £0.3B followed by Shingrix with growth of 13% to £0.8B.
- General Medicines increased 4% to £2.5 billion, while sales of its asthma and COPD treatment Trelegy rose 25% to £0.7 billion.
- In the quarter, non-GAAP EPS of £0.55 compares to £0.497 in the year-ago period.
More on GSK
- GSK plc 2025 Q3 - Results - Earnings Call Presentation
- GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
- GSK's Hidden Growth Engines Beyond HIV And Oncology
- GSK beats top-line and bottom-line estimates; raises FY25 outlook
- GSK secures exclusive rights to Syndivia’s preclinical ADC for advanced prostate cancer
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
